Table 1 Baseline and pathological characteristics before and after PSM between two group.
Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|
RRRH group (n = 10) | LRRH group (n = 36) | P-value | RRRH group (n = 10) | LRRH group (n = 20) | P-value | |
Gender, n (%) | 0.707 | 0.690 | ||||
Male | 6 (60.0%) | 25 (69.4%) | 6 (60.0%) | 14 (70.0%) | ||
Female | 4 (40.0%) | 11 (30.6%) | 4 (40.0%) | 6 (30.0%) | ||
Age, year, mean (SD) | 64.0 ± 8.8 | 66.1 ± 9.6 | 0.536 | 64.0 ± 8.8 | 65.6 ± 8.8 | 0.643 |
BMI, kg/m2, median | 23.5 (19–30) | 24 (18–30) | 0.646 | 23.5 (19–30) | 24 (18–30) | 0.681 |
ASA classification ≥ III, n (%) | 2 (20.0%) | 5 (13.9%) | 0.636 | 2 (20.0%) | 3 (15.0%) | > 0.999 |
Total bilirubin, µmol/mL, mean (SD) | 168.2 ± 87.7 | 239.4 ± 100.0 | 0.047 | 168.2 ± 87.7 | 218.3 ± 94.0 | 0.221 |
Preoperative PTBD, n (%) | 6 (60.0%) | 29 (80.6%) | 0.220 | 6 (60.0%) | 16 (80.0%) | 0.384 |
Bile reinfusion, n (%) | 4 (40.0%) | 14 (38.9%) | 1.000 | 4 (40.0%) | 7 (35.0%) | > 0.999 |
ICG R15, %, median | 8.8 (3.3–14.1) | 8.0 (1.2–18.4) | 0.783 | 8.8 (3.3–14.1) | 8.4 (1.2–13.6) | 0.713 |
Bismuth type, n (%) | > 0.999 | > 0.999 | ||||
I | 0 (0.0%) | 1 (2.78%) | 0 (0.0%) | 0 (0.0%) | ||
II | 1 (10.0%) | 5 (13.9%) | 1 (10.0%) | 1 (5.0%) | ||
III | 7 (70.0%) | 20 (53.6%) | 7 (70.0%) | 14 (70.0%) | ||
IV | 2 (20.0%) | 10 (27.8%) | 2 (20.0%) | 5 (25.0%) | ||
Tumor size, cm, mean (SD) | 2.1 ± 0.7 | 2.0 ± 0.9 | 0.821 | 2.1 ± 0.7 | 1.8 ± 0.6 | 0.322 |
AJCC T stage, n (%) | 0.636 | > 0.999 | ||||
T1 + T2 | 8 (80.0%) | 31 (86.1%) | 8 (80.0%) | 17 (85.0%) | ||
T3 + T4 | 2 (20.0%) | 5 (13.9%) | 2 (20.0%) | 3 (15.0%) | ||
